目的 研究半乳糖凝集素-3 (Galectin-3,Gal-3)的結(jié)構(gòu)、功能、與脂類代謝關(guān)系及其在下肢動(dòng)脈硬化閉塞癥的發(fā)生和進(jìn)展中的表達(dá)情況。
方法 對(duì)相關(guān)文獻(xiàn)進(jìn)行綜述分析。
結(jié)果 Gal-3參與炎癥反應(yīng)及脂類代謝紊亂,調(diào)節(jié)細(xì)胞的生長(zhǎng)、分化、黏附、凋亡和血管生成,參與動(dòng)脈硬化閉塞癥的發(fā)生和進(jìn)展。
結(jié)論 Gal-3與下肢動(dòng)脈硬化閉塞癥的發(fā)生、進(jìn)展和預(yù)后的相關(guān)性是肯定的,具有生物學(xué)標(biāo)志性意義。
引用本文: 祖紅林,張英男. 半乳糖凝集素-3與下肢動(dòng)脈硬化閉塞癥關(guān)系的研究進(jìn)展△. 中國(guó)普外基礎(chǔ)與臨床雜志, 2013, 20(4): 462-465. doi: 復(fù)制
1. | 王玉琦, 岳嘉寧, 符偉國(guó). 下肢動(dòng)脈硬化閉塞癥的外科治療進(jìn)展[J]. 中華臨床醫(yī)師雜志(電子版), 2009, 3(2):179-183. |
2. | 劉昌偉. 下肢動(dòng)脈硬化閉塞癥的外科治療[J]. 臨床外科雜志,2006, 14(5):265-266. |
3. | Aronow WS. Peripheral arterial disease of the lower extremities[J]. Arch Med Sci, 2012, 8(2): 375-388. |
4. | Sundblad V, Croci DO, Rabinovich GA. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues[J]. Histol Histopathol, 2011, 26(2):247-265. |
5. | Dumic J, Dabelic S, Flögel M. Galectins:an open-ended story[J]. Biochim Biophys Acta, 2006, 1760(4): 616-635. |
6. | Yang RY, Rabinovich GA, Liu FT. Galectins:structure, function and therapeutic potential[J]. Expert Rev Mol Med, 2008, 10:e17. |
7. | Idikio HA. Galectin-3 and Beclin1/Atg6 genes in human cancers:using cDNA tissue panel, qRT-PCR, and logistic regression modelto identify cancer cell biomarkers[J]. Plos One, 2011, 6(10):e26150. |
8. | Jara LJ, Medina G, Vera-Lastra O, et al. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases[J]. Autoimmun Rev, 2006, 5(3):195-201. |
9. | Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis[J]. Circulation, 2002, 105(9):1135-1143. |
10. | Hsu DK, Hammes SR, Kuwabara I, et al. Human T lymphotropicvirus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3[J]. Am J Pathol, 1996,148(5):1661-1670. |
11. | Kimata H. Enhancement of IgE production in B cells by neutrophils via galectin-3 in IgE-associated atopic eczema/dermatitis syndrome[J]. Int Arch Allergy Immunol, 2002, 128(2):168-170. |
12. | Fermino ML, Polli CD, Toledo KA, et al. LPS-induced galectin-3 oligomerization results in enhancement of neutrophil activation[J]. PloS One, 2011, 6(10): e20064. |
13. | Novak R, Dabelic S, Dumic J. Galectin-1 and galectin-3 expre-ssion profiles in classically and alternatively activated human macrophages[J]. Biochim Biophys Acta, 2012, 1820(9): 1383-1390. |
14. | Paclik D, Werner L, Guckelberger O, et al. Galectins distinctively regulate central monocyte and macrophage function[J]. Cell Immunol, 2011, 271(1): 97-103. |
15. | Papaspyridonos M, McNeill E, de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progressionthrough macrophage activation and monocyte chemoattraction[J]. Arterioscler Thromb Vasc Biol, 2008, 28(3): 433-440. |
16. | Sano H, Hsu DK, Apgar JR, et al. Critical role of galectin-3 in phagocytosis by macrophages[J]. J Clin Invest, 2003, 112(3): 389-397. |
17. | Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novelchemoattractant for monocytes and macrophages[J]. J Immunol,. |
18. | Nachtigal M, Al-Assaad Z, Mayer EP, et al. Galectin-3 expression in human atherosclerotic lesions[J]. Am J Pathol, 1998, 152(5): 1199-1208. |
19. | Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome[J]. Int J Immunopathol Pharmacol, 2011, 24(4):905-913. |
20. | Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products(AGE):a new member of the AGE-receptor complex[J]. Mol Med ,1995, 1(6):634-646. |
21. | Ahmad N, Gabius HJ, André S, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes[J]. J Biol Chem, 2004, 279(12):10841–10847. |
22. | Califice S, Castronovo V, Van Den Brûle F. Galectin-3 and cancer(Review)[J]. Int J Oncol, 2004, 25(4):983-992. |
23. | Ferrazzo KL, Neto MM, dos Santos E, et al. Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands[J]. J Oral Pathol Med, 2009, 38(9): 701-707. |
24. | Lee JH, Zhang X, Shin BK, et al. Mac-2 binding protein andgalectin-3 expression in mucinous tumours of the ovary:an anne-aling control primer system and immunohistochemical study[J]. Pathology, 2009, 41(3): 229-233. |
25. | Miranda FA, Hassumi MK, Guimaraes MC, et al. Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis[J]. J Histochem Cytochem, 2009, 57(7):665-673. |
26. | Nangia-Makker P, Balan V, Raz A. Galectin-3 binding andmetastasis[J]. Methods Mol Biol, 2012, 878: 251-266. |
27. | Shoeppner HL, Raz A, Ho SB, et al. Expression of an endogenous galactoside-binding lectin correlates with neoplastic progression in the colon[J]. Cancer, 1995, 75(12):2818-2826. |
28. | Xu XC, el-Nagger AK, Lotan R. Differential expression of gale-ctin-1 and galectin-3 in thyroid tumors:potential diagnostic impli-cations[J]. Am J Pathol, 1995, 147(3): 815-822. |
29. | Bresalier RS, Mazurek N, Sternberg LR, et al. Metastasis of human colon cancer is altered by modifying expression of the b galactoside-binding protein galectin-3[J]. Gastroenterology, 1998, 115(2):287-296. |
30. | Scott A, Mellor H. VEGF receptor trafficking in angiogenesis[J]. Biochem Soc Trans, 2009, 37(Pt 6):1184-1188. |
31. | Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6): 669-676. |
32. | Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenesis[J]. J Exp Med, 2010, 207(9): 1981-1993. |
33. | Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelialcells[J]. EMBO J, 2001, 20(11):2768-2778. |
34. | Markowska AI, Jefferise KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascularendothelial growth factor receptor 2 in human endothelial cells[J]. J Biol Chem, 2011, 286(34): 29913-29921. |
35. | Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis[J]. Am J Pathol, 2000, 156(3):899-909. |
36. | Saint-Lu N, Oortwijn BD, Pengon JN, et al. Identification ofgalectin-1 and galectin-3 as novel partners for von Willebrand factor[J]. Arterioscler Thromb Vasc Biol, 2012, 32(4):894-901. |
37. | Stowell SR, Arthur CM, Mehta P, et al. Galectin-1, -2, and-3exhibit differential recognition of sialylated glycans and blood group antigens[J]. J Biol Chem, 2008, 283(15):10109-10123. |
38. | , 165(4): 2156–2164. |
- 1. 王玉琦, 岳嘉寧, 符偉國(guó). 下肢動(dòng)脈硬化閉塞癥的外科治療進(jìn)展[J]. 中華臨床醫(yī)師雜志(電子版), 2009, 3(2):179-183.
- 2. 劉昌偉. 下肢動(dòng)脈硬化閉塞癥的外科治療[J]. 臨床外科雜志,2006, 14(5):265-266.
- 3. Aronow WS. Peripheral arterial disease of the lower extremities[J]. Arch Med Sci, 2012, 8(2): 375-388.
- 4. Sundblad V, Croci DO, Rabinovich GA. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues[J]. Histol Histopathol, 2011, 26(2):247-265.
- 5. Dumic J, Dabelic S, Flögel M. Galectins:an open-ended story[J]. Biochim Biophys Acta, 2006, 1760(4): 616-635.
- 6. Yang RY, Rabinovich GA, Liu FT. Galectins:structure, function and therapeutic potential[J]. Expert Rev Mol Med, 2008, 10:e17.
- 7. Idikio HA. Galectin-3 and Beclin1/Atg6 genes in human cancers:using cDNA tissue panel, qRT-PCR, and logistic regression modelto identify cancer cell biomarkers[J]. Plos One, 2011, 6(10):e26150.
- 8. Jara LJ, Medina G, Vera-Lastra O, et al. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases[J]. Autoimmun Rev, 2006, 5(3):195-201.
- 9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis[J]. Circulation, 2002, 105(9):1135-1143.
- 10. Hsu DK, Hammes SR, Kuwabara I, et al. Human T lymphotropicvirus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3[J]. Am J Pathol, 1996,148(5):1661-1670.
- 11. Kimata H. Enhancement of IgE production in B cells by neutrophils via galectin-3 in IgE-associated atopic eczema/dermatitis syndrome[J]. Int Arch Allergy Immunol, 2002, 128(2):168-170.
- 12. Fermino ML, Polli CD, Toledo KA, et al. LPS-induced galectin-3 oligomerization results in enhancement of neutrophil activation[J]. PloS One, 2011, 6(10): e20064.
- 13. Novak R, Dabelic S, Dumic J. Galectin-1 and galectin-3 expre-ssion profiles in classically and alternatively activated human macrophages[J]. Biochim Biophys Acta, 2012, 1820(9): 1383-1390.
- 14. Paclik D, Werner L, Guckelberger O, et al. Galectins distinctively regulate central monocyte and macrophage function[J]. Cell Immunol, 2011, 271(1): 97-103.
- 15. Papaspyridonos M, McNeill E, de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progressionthrough macrophage activation and monocyte chemoattraction[J]. Arterioscler Thromb Vasc Biol, 2008, 28(3): 433-440.
- 16. Sano H, Hsu DK, Apgar JR, et al. Critical role of galectin-3 in phagocytosis by macrophages[J]. J Clin Invest, 2003, 112(3): 389-397.
- 17. Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novelchemoattractant for monocytes and macrophages[J]. J Immunol,.
- 18. Nachtigal M, Al-Assaad Z, Mayer EP, et al. Galectin-3 expression in human atherosclerotic lesions[J]. Am J Pathol, 1998, 152(5): 1199-1208.
- 19. Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome[J]. Int J Immunopathol Pharmacol, 2011, 24(4):905-913.
- 20. Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products(AGE):a new member of the AGE-receptor complex[J]. Mol Med ,1995, 1(6):634-646.
- 21. Ahmad N, Gabius HJ, André S, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes[J]. J Biol Chem, 2004, 279(12):10841–10847.
- 22. Califice S, Castronovo V, Van Den Brûle F. Galectin-3 and cancer(Review)[J]. Int J Oncol, 2004, 25(4):983-992.
- 23. Ferrazzo KL, Neto MM, dos Santos E, et al. Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands[J]. J Oral Pathol Med, 2009, 38(9): 701-707.
- 24. Lee JH, Zhang X, Shin BK, et al. Mac-2 binding protein andgalectin-3 expression in mucinous tumours of the ovary:an anne-aling control primer system and immunohistochemical study[J]. Pathology, 2009, 41(3): 229-233.
- 25. Miranda FA, Hassumi MK, Guimaraes MC, et al. Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis[J]. J Histochem Cytochem, 2009, 57(7):665-673.
- 26. Nangia-Makker P, Balan V, Raz A. Galectin-3 binding andmetastasis[J]. Methods Mol Biol, 2012, 878: 251-266.
- 27. Shoeppner HL, Raz A, Ho SB, et al. Expression of an endogenous galactoside-binding lectin correlates with neoplastic progression in the colon[J]. Cancer, 1995, 75(12):2818-2826.
- 28. Xu XC, el-Nagger AK, Lotan R. Differential expression of gale-ctin-1 and galectin-3 in thyroid tumors:potential diagnostic impli-cations[J]. Am J Pathol, 1995, 147(3): 815-822.
- 29. Bresalier RS, Mazurek N, Sternberg LR, et al. Metastasis of human colon cancer is altered by modifying expression of the b galactoside-binding protein galectin-3[J]. Gastroenterology, 1998, 115(2):287-296.
- 30. Scott A, Mellor H. VEGF receptor trafficking in angiogenesis[J]. Biochem Soc Trans, 2009, 37(Pt 6):1184-1188.
- 31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6): 669-676.
- 32. Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenesis[J]. J Exp Med, 2010, 207(9): 1981-1993.
- 33. Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelialcells[J]. EMBO J, 2001, 20(11):2768-2778.
- 34. Markowska AI, Jefferise KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascularendothelial growth factor receptor 2 in human endothelial cells[J]. J Biol Chem, 2011, 286(34): 29913-29921.
- 35. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis[J]. Am J Pathol, 2000, 156(3):899-909.
- 36. Saint-Lu N, Oortwijn BD, Pengon JN, et al. Identification ofgalectin-1 and galectin-3 as novel partners for von Willebrand factor[J]. Arterioscler Thromb Vasc Biol, 2012, 32(4):894-901.
- 37. Stowell SR, Arthur CM, Mehta P, et al. Galectin-1, -2, and-3exhibit differential recognition of sialylated glycans and blood group antigens[J]. J Biol Chem, 2008, 283(15):10109-10123.
- 38. , 165(4): 2156–2164.